# An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice

> **NCT05369832** · PHASE4 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 139 (actual)

## Conditions studied

- Colitis, Ulcerative

## Interventions

- **DRUG:** Ozanimod

## Key facts

- **NCT ID:** NCT05369832
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-12-16
- **Primary completion:** 2025-01-21
- **Final completion:** 2025-04-11
- **Target enrollment:** 139 (ACTUAL)
- **Why stopped:** Business objectives have changed.
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05369832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05369832, "An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05369832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*